Epithelial ovarian cancer cell lines spontaneously derived from high-grade serous ascites of patients with recurring disease
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161767 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from high-grade serous ascites of patients with recurring disease and who had been treated with chemotherapy prior to collection. The ‘2’ after OV866(2) refers to the fact that this cell line was established from a second ascites sample from the patient |
| Alternate name: | OV-866 (2) |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement. |
| Additional notes: | Taken from female who was age 60 at diagnosis, BRCA hereditary was negative, disease stage was IIIC. No prioir personal history of cancer or prioir oncologic treatment, and was not chemotherapy naive at the time of sample collection |
| Receptors of note: | No |
| Cat. #: | 161767 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from ascites |
| Gender: | Female |
| Morphology: | Predominantly small epithelial type cells, often aggregated, and fibroblast shaped cells notably absent. Formed loose compat spheroids with irregular margins |
| Growth properties: | Adherent |
| Primary citation: | Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941 |
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
|---|---|
| Atmosphere: | Low oxygen conditions of 7% O2 and 5% CO2 |
| References: |
Vias et al. 2023. Elife. 11 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30 15(9):2566. PMID: 37174032 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.